# Advancing Toward a World Without Vision Loss From Diabetes: Insights From The Mary Tyler Moore Vision Initiative Symposium 2024 on Curing Vision Loss From Diabetes

## TL;DR

Experts discussed strategies to end vision loss from diabetes, focusing on new diagnostics, therapies, and patient-centered approaches.

## Contribution

The paper highlights new collaborations, clinical trials, and AI tools aimed at advancing diabetic retinal disease research.

## Key findings

- MTM Vision is launching clinical trials and a public awareness campaign to combat diabetic vision loss.
- AI-driven tools and big-data strategies are being used to improve DRD diagnosis and treatment personalization.
- The MTM Vision Biorepository is expanding to support multi-omics analyses of DRD mechanisms.

## Abstract

The Mary Tyler Moore Vision Initiative (MTM Vision) honors Mary Tyler Moore's commitment to ending vision loss from diabetes. Founded by Moore's husband, Dr. S. Robert Levine, MTM Vision aims to accelerate breakthroughs in diabetic retinal disease (DRD). At the MTM Vision Symposium 2024 on Curing Vision Loss from Diabetes, experts highlighted the urgent need for updated DRD staging systems, clinically relevant endpoints, and novel biomarkers to detect early disease changes. MTM Vision is advancing two clinical trials in collaboration with the DRCR Retina Network, launching a public awareness campaign, and welcoming Boehringer Ingelheim as the first founding industry member of its pre-competitive Consortium. Speakers emphasized big-data strategies and artificial intelligence (AI)-driven tools to improve DRD diagnosis, risk prediction, and personalized treatment. They also showcased new efforts to bridge academic discoveries with industry expertise, illustrating promising work on vascular regeneration and cellular senescence that may yield future therapies. The MTM Vision Biorepository and Resource Center is expanding tissue collections, enabling multi-omics analyses to study DRD mechanisms. Patient voices were central to the discussion, with calls for enhanced patient-reported outcomes, caregiver support, and broader education on DRD's risks. The symposium also underscored the importance of integrating mental health, quality of life measures, and ongoing patient input to guide clinical research.